Search for: "In Re: White v."
Results 3501 - 3520
of 4,470
Sorted by Relevance
|
Sort by Date
13 Apr 2008, 11:00 pm
Rowling v. [read post]
3 Jul 2018, 6:43 am
” The most significant ADEA case that divorces the ADEA from Title VII precedent is Gross v. [read post]
19 Aug 2011, 7:30 am
") Remember Ricci v. [read post]
10 May 2012, 7:58 am
" "Provided they're not a felon, I guess," Rallo replied. [read post]
1 Sep 2016, 5:04 am
But this was the DEA, the government, and they’re special. [read post]
15 Oct 2010, 9:24 am
The Supreme Court's 2008 ruling in Baze v. [read post]
29 Apr 2010, 4:21 pm
What would they do if I incorrectly cited Anders v. [read post]
11 Jul 2023, 7:33 am
” “Michael V. [read post]
22 Feb 2012, 3:22 am
A case of good lawyering was shown by the 8th’s decision a couple of weeks back in State v. [read post]
10 May 2012, 7:58 am
" "Provided they're not a felon, I guess," Rallo replied. [read post]
14 Feb 2016, 11:07 am
When he walked back to his table, I leaned over to my wife and whispered, "We're losing Dickerson. [read post]
13 Nov 2018, 5:30 am
Aguayo v. [read post]
12 Aug 2012, 6:30 am
Association v. [read post]
1 Apr 2016, 4:12 am
David Phippen predicted the outcome of the Supreme Court’s 4-4 decision this week in Friedrichs v. [read post]
30 Apr 2021, 1:17 pm
However, we think Garland's decision is simpler in one regard: Trump's conviction under § 2383 would not prevent his serving in the White House again. [read post]
30 Jul 2023, 11:24 am
And so they’re gonna have a natural disadvantage, and Trump’s going to take advantage of it. [read post]
9 Aug 2016, 10:44 am
We can infer that person did so probably with the blessing if not the instruction of the White House. [read post]
22 Jun 2010, 3:40 pm
Kelly v. [read post]
15 Jan 2010, 10:26 am
Pennsylvania:Prigg v. [read post]
9 Mar 2020, 1:21 pm
Biosimilar Markets [I entered in media res]· Eva Temkin, Acting Director for Policy, Office of Therapeutic Biologics and Biosimilars, CDER, FDA · Christine Simmon, Executive Director, Biosimilars Council, AAM: barriers to entry for biosimilars: exclusionary contracts, rebates, stakeholder misinformation. misinformation can include explicit and implicit, including policies such as naming conventions and the very existence of the interchangeable category,… [read post]
